Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HPGD | P15428 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | NSD2 | O96028 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8485186 | 0.77 | KDM4E (0.34) | ALDH1A1HPGDKDM4EGAAALOX12 | |
| SCHEMBL1773296 | 0.76 | NSD2 (0.46) | ALDH1A1HPGDKDM4EGAAALOX12 | |
| SCHEMBL11797517 | 0.74 | HEXA (0.40) | ALDH1A1HPGDKDM4EGAAALOX12 | |
| SCHEMBL4158909 | 0.73 | KDM4E (0.49) | ALDH1A1HPGDKDM4EGAAALOX12 | |
| SCHEMBL6510269 | 0.72 | KDM4E (0.36) | ALDH1A1HPGDKDM4EGAAALOX12 | |
| SCHEMBL15018068 | 0.72 | HEXA (0.41) | ALDH1A1HPGDKDM4EGAAALOX12 | |
| SCHEMBL15018562 | 0.70 | P2RX4 (0.37) | ALDH1A1HPGDKDM4EGAAALOX12 | |
| SCHEMBL15018691 | 0.70 | NPC1 (0.49) | ALDH1A1HPGDKDM4EMAPTHSD17B10 | |
| SCHEMBL8521442 | 0.70 | ALDH1A1 (0.38) | ALDH1A1HPGDKDM4EGAAALOX12 | |
| SCHEMBL11881952 | 0.69 | MAPT (0.53) | ALDH1A1HPGDKDM4EGAAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1548121-B1 | Physiologically active substances | EISAI R&D MAN CO LTD (JP) | 2015-04-29 | — | — | EP | disclosed |
| CN-1665807-B | Physiologically active substance | MICROBIOPHARM JAPAN CO LTD | 2013-09-11 | — | — | CN | disclosed |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | MIYANO MASAYUKI | 2011-06-09 | — | — | US | disclosed |
| US-7932083-B2 | Ferrodoxins; hydroxylases; self-replicating plasmid | MERCIAN CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7893068-B2 | Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy | MERCIAN CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| EP-2266978-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2010-12-29 | — | — | EP | disclosed |
| CN-1671856-B | Novel physiologically active substances | EISAI R&D MAN CO LTD | 2010-05-12 | — | — | CN | disclosed |
| US-7655442-B2 | Efficiently producing a macrolide compound, in which a cyclodextrin is made to be present in a culture broth of actinomycetes; antitumor agents | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20100021918-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING SPLICING DEFECTS AS INDEX | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-2145886-A1 | TWELVE-MEMBERED CYCLOMACROLACTAM DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-20060235002-A1 | Novel physiologically active substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1710244-A1 | METHOD OF STABILIZING MACROLIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-1705247-A1 | DNA PARTICIPATING IN HYDROXYLATION OF MACROLIDE COMPOUND | MERCIAN CORPORATION (JP) | 2006-09-27 | — | — | EP | disclosed |
| US-20060009439-A1 | Novel physiologically active substances | MERCIAN CORPORATION (JP) | 2006-01-12 | — | — | US | disclosed |
| US-20050245514-A1 | Novel physiologically active substances | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| CN-1671856-A | Novel physiologically active substances | MERCIAN CORP (JP) | 2005-09-21 | — | — | CN | disclosed |
| CN-1665807-A | Novel physiolgically active substances | MERCIAN CORP (JP) | 2005-09-07 | — | — | CN | disclosed |
| EP-1548121-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-06-29 | — | — | EP | disclosed |
| EP-1541570-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE | MERCIAN CORPORATION (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1508570-A1 | NOVEL PHYSIOLGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2005-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245514-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | ALDH1A1 133/4885HPGD 76/4885KDM4E 4239/4885 |
| US-20100021918-A1 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING SPLICING DEFECTS AS INDEX | RBM17, SF3B5, RBM22 | ALDH1A1 2241/4885HPGD 2752/4885KDM4E 4158/4885 |
| US-20060009439-A1 | Novel physiologically active substances | HIF1A, HIF1AN, VEGFA | ALDH1A1 108/4885HPGD 82/4885KDM4E 3533/4885 |
| US-20060235002-A1 | Novel physiologically active substance | HIF1AN, HIF1A, VEGFA | ALDH1A1 119/4885HPGD 292/4885KDM4E 3844/4885 |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDAC1 | ALDH1A1 2310/4885HPGD 1714/4885KDM4E 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.